German Diagnostics: Life Gets Hard
In the past year, Germany, the largest health-care market in Europe and long considered a model of high-quality medical egalitarianism, has cut reimbursement for many in vitro diagnostics tests by 15-20%, mirroring trends in other European countries. In response, German laboratories are consolidating to reap the benefits of economies of scale, while their suppliers are paring expenses, reorganizing internally, and cutting prices.
You may also be interested in...
A draft EU guideline explains how disease registries can be used to supplement evidence in the pre-authorization phase and provide infrastructure for post-authorization evidence generation.
Drug companies have their last chance to negotiate which documents and information Italy’s regulator, AIFA, will be entitled to request of them when they submit pricing and reimbursement applications.
Sandoz sees key opportunities ahead in both the US and Canadian biosimilars markets, the firm’s US vice-president for marketing, market access and patient services, Sheila Frame, tells Generics Bulletin in the second part of an exclusive interview.